Tundra Space

Tundra Space

Book DemoDirectoryLog InSign Up

Clinical Research Directory

Browse clinical research sites, groups, and studies.

SitesGroupsStudies
Back to Studies
RECRUITING
NCT05829655
EARLY_PHASE1

Measuring Acute Drug Demand in Humans

Sponsor: University of Maryland, Baltimore

View on ClinicalTrials.gov

Summary

This research is being done to evaluate whether suvorexant may reduce the use of, subjective liking, and demand for various drugs.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

75

Start Date

2023-08-08

Completion Date

2028-01-01

Last Updated

2026-06-23

Healthy Volunteers

Yes

Conditions

Opioid Use DisorderOpioid Dependence

Interventions

DRUG

Drug A (Blinded Drug)

Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).

DRUG

Drug B (Blinded Drug)

Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).

DRUG

Drug C (Blinded Drug)

Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).

DRUG

Drug D (Blinded Drug)

Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).

DRUG

Suvorexant (20mg/day)

Double blind administration of suvorexant once per day during residential stay until discharge.

DRUG

Placebo

Double blind administration of placebo once per day during residential stay until discharge.

Locations (1)

General Clinical Research Center

Baltimore, Maryland, United States